TrialPanorama/Dataset huggingface dataset:
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Effects of Craniosacral Therapy on Chronic Neck Pain: A Randomized Controlled Trial
Brief Summary: The purpose of this randomized controlled trial is to determinate the efficacy and safety of Craniosacral Therapy in the treatment of chronic unspecific neck pain.


Options:
A: Inclusion Criteria:

* being between 18 and 65 years old; having mechanical neck pain with or without symptoms that radiated to the head and/or upper limbs (Guzman et al., 2009b); and
* scoring 10% or higher on the Neck Disability Index (NDI) or 2 points or more on the Visual Analogue Scale (VAS) of pain at initial evaluation (Farrar et al., 2001; Cleland et al., 2007).

Exclusion Criteria:

* Neck pain due to neoplasia, metastasis, severe osteoporosis, infectious or inflammatory processes, fractures, congenital anomalies, herniated disc, whiplash or cervical stenosis;
* evidence of cervical spinal cord compromise or radiculopathy; previous neck surgery;
* neck pain accompanied by dizziness caused by vertebrobasilar insufficiency or by headaches excluding those of cervical origin; and
* pregnant women. Patients were also excluded if they had received physiotherapy treatment in the previous three months; and had pending legal actions.
B: Inclusion Criteria:

* Active myofascial trigger point at the upper trapezius

Exclusion Criteria:

* Diagnosed fibromyalgia
* Cervical radiculopathy
* Facial neuralgia
* Coagulation alteration
* Cancer
* Allergy (included needles)
* History of cervical or shoulder surgery
* History of deep venous thrombosis
* History of myopathy
* History of infiltration at upper trapezius trigger point
* Anticoagulant medication
* Aspirin intake during the last 3 days
* Drug intake (AINES, narcotics, antiepileptics, or any other analgesic medication)
* Pregnancy
C: Inclusion Criteria:

* Chronic unspecific neck pain for at least 3 months
* Mean neck pain of moderate intensity (\>/=45mm on VAS)
* Therapy-naive subjects

Exclusion Criteria:

* Specific neck pain due to severe deformity of the spine, prolapse, rheumatic or neurological disorder, trauma, operation or cancer
* other severe somatic or psychiatric comorbidity
* pregnancy
* regular intake of opiates, corticosteroids (\>10mg prednisolon), muscle relaxants or antidepressants
* recent invasive or manipulative treatment of the spine
* participation in other clinical trials
D: Inclusion Criteria:

* Patients of both sexes, aged between 20 and 60 years, in an active state of pain and diagnosed with muscle breakdown

Exclusion Criteria:

- Patients who are pregnant, have pacemakers and surgically operated in the area to be treated

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Metformin Versus Metfotmin Plus Low-dose Spironolactone in the Treatment of Overweight/Obese Patients With Polycystic Ovary Syndrome: a Randomized Study
Brief Summary: The investigators examined whether a combined therapy with low-dose spironolactone plus metformin is more effective than metformin alone in 52 overweight/obese Polycystic Ovary Syndrome (PCOS) patients.


Options:
A: Inclusion Criteria:

* normal weight women with Polycystic ovary syndrome, diagnosed in accordance with Rotterdam Consensus Conference Criteria 2003.

Exclusion Criteria:

* pregnancy
* past history of cardiovascular disease, diabetes mellitus (or impaired glucose tolerance as determined by a standard 75 g oral glucose tolerance test), hypertension
* significant liver or renal impairment
* other hormonal dysfunction (hypothalamic, pituitary, thyroidal or adrenal causes for the clinical signs)
* neoplasms
* unstable mental illness
B: Inclusion Criteria

* Eight or fewer menstrual cycles in the past year or intermenstrual periods of 45 days or longer
* Elevated testosterone level
* Good general health
* Sperm concentration in partner of 20 million/ml or greater
* Ability to have intercourse 2-3 times per week
* One functional fallopian tube and normal uterine cavity
C: Inclusion Criteria:

* PCO - ESHRE/ASRM criteria:oligomenorrhea (\<8 spontaneus menses per year) and hyperandrogenism(hirsutism or acne) or hyperandrogenemia(testosterone \> 70 ng/ml) normal prolactin, TSH, 17-OH progesterone no evidence of androgen producing malignancy, Cushing's syndrome or acromegaly age 18-40 reliable use of birth control pill for at least 3 months and no plans of pregnancy

Exclusion Criteria:

* elevated creatinine kinase above 2 times upper limit of normal or liver enzymes (transaminase) above 2 times of upper limit of normal use of any following medications: cyclosporine, fibrates niacin,antifungal agents, macrolide antibiotics use of oral contraceptives and other steroid hormones 3 months prior to the study
D: Inclusion Criteria:

* Overweight/obese patients with PCOS

Exclusion Criteria:

* Other causes of hyperandrogenism and
* Use of drugs including:

  * oral contraceptive
  * anti-hypertensive agents
  * anti-diabetic drugs
  * agents for weight loss

Answer: D
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Double Blind Sham Controlled Randomised Trial of Intraperitoneal Bupivacaine During Acute Laparoscopic Cholecystectomy
Brief Summary: Laparoscopic cholecystectomy (removal of the gall bladder via 'keyhole surgery') is a common procedure. This can be performed as an emergency operation when a patient has a complication of gall stones such as acute inflammation or pancreatitis. There are several trials which demonstrate that placing local anaesthetic inside the abdomen at the site of gall bladder surgery during a planned elective operation decreases post operative pain. This is the first trial to investigate the efficacy of this local anaesthetic during emergency cholecystectomy.


Options:
A: Inclusion Criteria:

* Elective laparoscopic cholecystectomy
* 18 years old or over

Exclusion Criteria:

* Emergency surgery
* Under 18 year olds
B: Inclusion Criteria:

* patients undergoing emergency cholecystectomy for cholecystitis or gall stone pancreatitis

Exclusion Criteria:

* patients undergoing planned elective cholecystectomy
C: Inclusion Criteria:

* Programmed Cholecystectomy
* Laparoscopy
* Man and woman
* ≥ 18
* ASA 1 or 2
* Not living alone
* Patient receiving social security coverage
* Signature of Informed Consent Form

Exclusion Criteria:

* Cholecystectomy emergency
* Patient minor
* Pregnant woman (pregnancy test) or during breastfeeding
* Conversion to laparotomy
* Patient anticoagulant curative dose
* Living alone
* Patient addict
* Peptic Ulcer
* Refusal to enter the protocol
* Chronic requiring analgesics long-term
* Immunosuppression
* Long-term Treatment with corticosteroids
* Discovery intraoperative calculation in the bile duct
* Contraindication to ropivacaine (see cons-indications to ropivacaine)
* Hypersensitivity to study treatment or concomitant medications anesthesia
* Cardiac or unbalanced epileptic patients (due to the risk of cardiovascular and neurological local anesthetics)
* Patients ASA ≥ 3
* Patient \<50 kg
D: Inclusion Criteria:

* Age\>18 years old, ASA 1 and 2
* Gallbladder adenomatous polyposis and cholelithiasis with no byochemical, clinical and instrumental evidence of acute cholecystitis at the moment of surgery.

Exclusion Criteria:

* Age\<18 years old
* Pregnancy
* Previous major surgery of the supramesocholic compartment
* Acute cholecystitis
* Choledocolitiasis
* Acute pancreatitis at the moment of surgery
* Laparotomic conversion during surgery

Answer: B
Please select the eligibility criteria that correspond to the clinical trial below.
Title: N/A
Brief Summary: Millions of children in North America receive an annual flu vaccination, many of whom are at risk of experiencing severe distress. Children frequently use technologically advanced devices such as computers and cell phones. Based on this familiarity, the investigators introduced another sophisticated device - a humanoid robot to- interact with children during their vaccination. The investigators hypothesized that these children would experience less distress than children who did not have this interaction.


Options:
A: Inclusion Criteria:

* Children aged 2 to 18 years undergoing an LP

Exclusion Criteria:

* Children who had already participated or used the LP pillow
* medical condition (orthopaedic anomaly) contraindicating the use of the LP pillow
* Parents refusal
B: Inclusion Criteria:

* Age 4 to 17 years
* Presence of intellectual disability
* Need of peripheral IV line or venipuncture
* Informed consent signed by parents or legal guardians

Exclusion Criteria:

* Presence of abrasion, infection or break in skin in the area of Buzzy® placement
* Cold hypersensibility
C: Inclusion Criteria:

* Children attending the pediatric ED between the ages of 3 and 6 years - Undergoing an IV placement
* Conscious
* Have sufficient knowledge of the English language to understand and follow instructions and complete the age-appropriate pain assessment

Exclusion Criteria:

* Children with hearing impairments, developmental disabilities, or sensory impairment to pain (e.g., spina bifida)
* Children will be excluded at the discretion of the attending staff (e.g., child in critical condition; requires urgent IV placement; or has altered level of consciousness).
D: Inclusion Criteria:

* ages 5-9 years,
* boys and girls

Exclusion Criteria:

* children with pervasive developmental disability

Answer: D
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Prospective Study of the Feedback From an Adherence Monitor on Asthma Control
Brief Summary: Inhaled medications are the mainstay of the therapeutic management of respiratory disorders. Considered by many to be 'simple' and 'easy' to use, clinicians are aware that inhalers are often improperly used. However, there is no tool that can detect and record errors in either the timing or the method dose administration

The investigators designed a device that makes an acoustic record each time an inhaler is used. Opening the device makes an acoustic file which is recorded, this file is "time-stamped" which means that the timing of drug administration is recorded. When the device is retrieved and acoustic analysis performed, the steps involved in using the inhaler can be determined. Hence, the subjects inhaler technique is assessed and errors in the inhaler use identified. Together this means that errors in inhaler technique and timing of use can be quantified.

In this study the investigators attached the device to a discus dry powder inhaler. In order to eliminate the behavioral component of adherence and identify the mechanical issues associated with effective inhaler use the investigators studied subjects who were already in Hospital and already prescribed a discus inhaler. The investigators hypothesized that the device would identify which errors in technique were the most common and that this would provide insight into how these errors might be eliminated.


Options:
A: Inclusion Criteria:

* Patient with poorly controlled asthma

Exclusion Criteria:

* Patient under age of 12
* Not possessing a mobile phone and who don't have adequate command of the English language
B: Inclusion Criteria:

* Parents of children, aged 4-12 with moderate to severe asthma
C: Inclusion Criteria:

* Patients prescribed therapy equivalent to step 3 or higher on the Asthma Management Guidelines for at least 3 months
* At least one exacerbation in the previous year with systemic glucocorticoids
* Uncontrolled/Partially Controlled Asthma by GINA guidelines

Exclusion Criteria:

* Allergy to salmeterol/fluticasone
* Patients Controlled by GINA guidelines
D: Inclusion Criteria:

* adults predominantly African American and Hispanic/Latino with uncontrolled asthma recruited from low income urban neighborhoods

Exclusion Criteria:

* severe psychiatric or cognitive problems that would make it impossible to understand and complete the protocol.

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Dose-Response of Manipulation for Cervicogenic Headache
Brief Summary: This study will determine the number of visits to a chiropractor for spinal manipulation and light massage necessary for the optimal relief of cervicogenic headache (headache with associated neck pain). Effectiveness of care will also be determined.


Options:
A: Inclusion Criteria:

* chronic cervicogenic headache
* threshold pain level
* threshold headache frequency
* independently ambulatory
* English literate
* candidate for spinal manipulation

Exclusion Criteria:

* contraindication to thrust spinal manipulation or massage
* most other headache types
* Recent manual/exercise therapy from licensed provider for head/neck
* threshold pain medication use
* pregnancy
* involvement with another pain study
* suspicion of unmanaged depression
* most cancers
* hypertension (at least stage II)
* complicating neurological/spinal conditions
* pre-randomization noncompliance or cannot/will not comply with protocols
* health-related litigation, claims, or disability compensation
B: Inclusion Criteria:

* Patients who come to consultation of Primary Care for neck pain without structural hurt or irradiation, with muscular contraction and functional and postural limitation.

Exclusion Criteria:

* Injuries of skin (dermatitis, burns, sores, skin cancer) in the zone to massaging
* Structural injuries (bony fractures or injuries of muscles and tendons) in the zone to massaging
* Hemorrhage or tendency to suffer hemorrhage
* Chronic, serious diseases
* Malignant diseases and marked physical deterioration
* Psychiatric disorders
* Sensitive alterations
* Treatment with drugs of second or third level of the scale of the WHO which difficult to estimate changes for auto-acupressure
* No sign the informed consent
* Difficulty of reading comprehension or visual alterations
C: Inclusion Criteria:

* Age between 18 to 30 years
* Participants presented with interscapular pain
* Forward head posture with active trigger points in rhomboid muscle
* Segmental hypomobility in upper thoracic identified with positive springing test

Exclusion Criteria:

* Participants who demonstrated contraindication to manipulation
* Open wounds or Trauma to the area which occurred less than two months prior treatment
* Any neurological compromise
* Mid scapular pain due to degenerative process or osteoporosis
D: Inclusion Criteria:

1. Non-specific neck pain for 2-6 weeks.
2. Unilateral neck pain
3. Patients' age group between 25 - 40.
4. On VAS scale pain intensity \>4.

Exclusion Criteria:

1. Cervicogenic headache.
2. Tumor of cervical spine.
3. Whiplash injury.
4. Cervical Fractures
5. Normal ROM of cervical spine.

Answer: A
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Safeguarding the Brains of Our Smallest Children - a Pilot Study
Brief Summary: Regional tissue oxygenation (rStO2) can be monitored by near-infrared spectroscopy. The investigators planned a SafeBoosC phase II trial to test if a reduction of the burden of hyper- and hypoxia can be accomplished during the first three days of life in infants born before 28 completed weeks of gestation. The investigators developed a treatment guideline and a randomised trial design to evaluate if cerebral rStO2 spent out of range in %hours can be reduced by 50%. The present trial is a non-randomised pilot study of the intervention in 10 infants.


Options:
A: Inclusion Criteria:

* Infants with a minimal gestational age of 24 weeks 0 days to 27 completed weeks (up to 27 6/7ths) by best obstetrical estimate
* Infants who will receive full resuscitation as necessary, i.e., no parental request or physician decision to forego resuscitation
* Infants whose parents/legal guardians have provided consent for enrollment, or
* Infants without known major congenital malformations

Exclusion Criteria:

* Any infant transported to the center after delivery
* Infants whose parents/legal guardians refuse consent
* Infants born during a time when the research apparatus/study personnel are not available
* Infants \< 24 weeks 0 days or \> 28 weeks 0 days, completed weeks of gestation
B: Inclusion Criteria:

* Neonates born more than 12 weeks preterm (gestational age up to 27 weeks and 6 days).
* Decision to conduct full life support.
* Possibility to place cerebral NIRS oximeter within 3 hours after birth.
* Obtained parental signed written informed consent.

Exclusion Criteria:

* A clinical decision not to provide full life support.
* No possibility to place the cerebral NIRS oximeter within 3 hours after birth.
* Lack of parental signed written informed consent.
C: Inclusion Criteria:

* gestational age at birth less than 28 completed weeks
* cerebral oximeter in place at 3 hours after birth

Exclusion Criteria:

* decision not to provide full life support
D: Inclusion Criteria:

* Preterm neonate \<34+0 weeks after caesarean section
* Decision to conduct full life support
* Written informed consent

Exclusion Criteria:

* No decision to conduct full life support
* No written informed consent
* Congenital malformation

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Prevention of Ovarian Hyperstimulation Syndrome in GnRH Agonist IVF Cycles: Randomized Study Comparing Hydroxyethyl Starch Versus Cabergoline and Hydroxyethyl Starch
Brief Summary: The purpose of this study is to assess whether, in GnRH agonist in vitro fertilization (IVF) cycles, where there is a risk of ovarian hyperstimulation syndrome (OHSS), the addition of cabergoline to the hydroxyethyl starch infusion could decrease OHSS incidence and severity.


Options:
A: Inclusion Criteria:

* to be at risk of OHSS were invited to participate in the study

Exclusion Criteria:

* age \> 40 years
B: Inclusion Criteria:

1. Age \<or= 35, BMI \<or= 30
2. Long protocol GnRH agonist cycles
3. Estradiol level on day of HCG \>or= 3500 pg/ml
4. Retrieving more than 15 oocytes

Exclusion Criteria:

1. Male factor
2. Uterine factor
C: Inclusion Criteria:

* Patients undergoing ovarian stimulation for IVF-ET with long GnRH agonist protocol and at high risk of developing OHSS \[ have more than 20 follicles ( 90% of them less than 14 mm in mean diameter) and serum estradiol ≥ 3000 pg/ml\]

Exclusion Criteria:

* Fibrosis of lung,
* swelling or inflammation around the heart or lung,
* hypertension,
* liver disease,
* heart valve disease and
* allergy to cabergoline or ergot derivatives.
D: Inclusion Criteria:

* patients at risk of developing OHSS, defined by the development of 20-30 follicles larger than 12 mm in diameter and retrieval of more than 20 oocytes
* ovarian stimulation with long protocol

Exclusion Criteria:

* coasting cases

Answer: A
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Prevention of Ovarian Hyperstimulation Syndrome in GnRH Agonist IVF Cycles: Randomized Study Comparing Hydroxyethyl Starch Versus Cabergoline and Hydroxyethyl Starch
Brief Summary: The purpose of this study is to assess whether, in GnRH agonist in vitro fertilization (IVF) cycles, where there is a risk of ovarian hyperstimulation syndrome (OHSS), the addition of cabergoline to the hydroxyethyl starch infusion could decrease OHSS incidence and severity.


Options:
A: Inclusion Criteria:

* Patients undergoing ovarian stimulation for IVF-ET with long GnRH agonist protocol and at high risk of developing OHSS \[ have more than 20 follicles ( 90% of them less than 14 mm in mean diameter) and serum estradiol ≥ 3000 pg/ml\]

Exclusion Criteria:

* Fibrosis of lung,
* swelling or inflammation around the heart or lung,
* hypertension,
* liver disease,
* heart valve disease and
* allergy to cabergoline or ergot derivatives.
B: Inclusion Criteria:

* to be at risk of OHSS were invited to participate in the study

Exclusion Criteria:

* age \> 40 years
C: Inclusion Criteria:

* patients at risk of developing OHSS, defined by the development of 20-30 follicles larger than 12 mm in diameter and retrieval of more than 20 oocytes
* ovarian stimulation with long protocol

Exclusion Criteria:

* coasting cases
D: Inclusion Criteria

1. Signed Informed Consent Form, prior to screening evaluations
2. In good physical and mental health
3. Pre-menopausal females between the ages of 21-37 years (both inclusive) at the time of randomisation
4. Infertility for at least 1 year before randomisation, except for proven bilateral tubal infertility

Exclusion Criteria

1. Any clinically significant systemic disease
2. Endocrine or metabolic abnormalities (pituitary, adrenal, pancreas, liver or kidney)
3. History of recurrent miscarriage
4. Undiagnosed vaginal bleeding

Answer: B
Please select the eligibility criteria that correspond to the clinical trial below.
Title: A Randomised Control Trial of a Standardised and User-friendly Real-time PCR Assay for the Diagnosis of TB Using Tracheal Aspirates Obtained From Patients in the ICU
Brief Summary: Aim:

To evaluate the diagnostic utility and impact on patient outcomes of an automated PCR (Gene Xpert® MTB/RIF), in a group of patients with suspected pulmonary TB who are mechanically ventilated in ICU, using tracheal aspirates.

Hypothesis:

Gene Xpert is an accurate tool for the diagnosis of TB in the Intensive Care Unit and will impact on rates of treatment initiation and hospital stay.


Options:
A: Inclusion Criteria:

* HIV-infected (1x rapid HIV test positive)
* Considered TB suspect by attending doctor (must comprise at least 1 of the following: current fever or cough, drenching night sweats, self-reported LOW)
* Illness severity sufficient to warrant hospitalization
* ≥18 years old
* Provision of informed consent

Exclusion Criteria:

* HIV-uninfected
* Patients receiving any anti-TB medication in the 60 days prior to testing
* Unable to provide 30mls urine
* Inability to provide informed consent
B: Inclusion Criteria:

All HIV-infected men and women \> 18 years of age with newly diagnosed HIV at the 12 study clinics will be asked to participate in the study.

Exclusion Criteria:

* Patients will be excluded from participation if they have a current diagnosis of TB and/or if they are currently taking IPT, TB treatment and/or ART.
* Patients will also be excluded from participation if they cannot speak English or Chichewa;
* if they have a language or hearing impairment; or
* if they are prisoners.
C: Inclusion criteria:

1. Children aged 2 to 59 months
2. Newly hospitalized for severe pneumonia defined using WHO criteria as cough or difficulty in breathing with:

   1. Peripheral oxygen saturation \< 90% or central cyanosis, or
   2. Severe respiratory distress (e.g. grunting, nasal flaring, very severe chest indrawing), or
   3. Signs of pneumonia, defined as cough or difficulty in breathing with fast breathing (tachypnea) and/or chest indrawing, with any of the following danger signs:

      * Inability to breastfeed or drink,
      * Persistent vomiting
      * Lethargy or reduced level of consciousness
      * Convulsions,
      * Stridor in calm child
      * Severe malnutrition
3. Informed consent signed by parent/guardian

Exclusion criteria:

- Ongoing TB treatment or history of intake of anti-TB drugs in the last 6 months
D: Inclusion criteria:

1. Any ventilated patients over 18 years of age with suspected TB (suggestive pulmonary infiltrates, a history of constitutional symptoms preceding the ICU admission, or patients known or suspected to be infected with the human immunodeficiency virus (HIV)).

Exclusion criteria:

1. Patients known to have active TB or to already be on antituberculous medication.

Answer: D